Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly sourcing innovation from China as a wave of patent expirations approaches.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Major Western pharmaceutical companies are increasingly turning to China as a source of new drug candidates, as the industry faces a looming "patent cliff" that threatens revenue from existing blockbuster treatments.
The patent cliff refers to the expiration of patents protecting a number of major drugs, which will expose these products to generic competition and significant revenue losses for the companies that developed them.
In response, biopharma firms have pursued multibillion-dollar licensing and acquisition deals to secure promising compounds developed by Chinese biotech companies, seeking to replenish their pipelines.
The trend reflects a broader shift in where pharmaceutical innovation is being sourced, with Chinese biotech firms increasingly recognized for developing competitive drug candidates at lower cost than their Western counterparts.
Analysts expect the pace of such deals to continue as Western companies look to offset the financial impact of upcoming patent expirations through partnerships with Chinese drug developers.
Sources
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals — CNBC — Top News
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Big Pharma's China Deal Spree Grows With Latest Tie-Up Worth Up to $7.8 Billion
Western biopharmaceutical companies are increasingly turning to China to source innovation as the industry's looming patent cliff draws closer, according to CNBC.
Nike shares fall as retailer posts weak sales, announces layoffs amid restructuring
The company is expected to report another quarter of declining sales as it works to turn around its business, including in China.
Nike announces layoffs amid restructuring as sales decline continues
The sportswear giant is expected to post another quarter of falling sales as it works to turn its business around and revive growth in China.
What went wrong at Nike? How the sportswear giant lost its edge
A series of self-inflicted missteps has weighed on the world's largest sportswear brand in recent years, according to a BBC Business report.
Putin Offers China Partnership on Siberian Copper Deposit
Russian President Vladimir Putin said Chinese companies, among the most active investors in the Russian Far East, could join the development of one of Siberia's largest copper deposits, Kommersant reports.
China's Tang disqualified from Asian Games judo quarter-finals after alleged bite
Tang Jing's opponent's coach claimed their athlete was left with bite marks on her arm during the bout.